Enhanced expression of CD39 and CD73 on T cells in the regulation of anti-tumor immune responses. (1st January 2020)
- Record Type:
- Journal Article
- Title:
- Enhanced expression of CD39 and CD73 on T cells in the regulation of anti-tumor immune responses. (1st January 2020)
- Main Title:
- Enhanced expression of CD39 and CD73 on T cells in the regulation of anti-tumor immune responses
- Authors:
- Shevchenko, Ivan
Mathes, Andreas
Groth, Christopher
Karakhanova, Svetlana
Müller, Verena
Utikal, Jochen
Werner, Jens
Bazhin, Alexandr V.
Umansky, Viktor - Abstract:
- ABSTRACT: Synthesis of extracellular adenosine by the ectonucleotidases CD39 and CD73 represents an important pathway of immune suppression in the tumor microenvironment. Using two mouse models ( RET transgenic melanoma and Panc02 orthotopic pancreatic adenocarcinoma), we identified an elevated frequency of ectonucleotidase-expressing T cells in tumors and spleens. Importantly, these ectonucleotidase-positive T cells also showed a pronounced expression of PD-1. Conversely, the PD-1 + T cell subsets in tumors contained substantially larger proportions of ectonucleotidase-expressing cells compared to their counterparts lacking PD-1 expression. Our in vitro experiments showed that the activation of normal T cells resulted in an increase in the CD39 expression. CD39 + and CD73 + T cells displayed effector or memory phenotypes and produced IFN-γ, thereby linking ectonucleotidase expression to T cell effector functions. An accumulation of conventional and regulatory T cells expressing CD39 and/or CD73 was also detected in the peripheral blood of patients with melanoma and pancreatic cancer. Moreover, we demonstrated a significant association between low frequencies of circulating CD73 + CD8 + T cells and CD73 + CD4 + regulatory T cells and better overall survival of melanoma patients. Tumor-derived soluble factors (in particular, TGF-β) significantly enhanced the frequencies of ectonucleotidase-expressing cells in mice. Our findings suggest that the upregulation ofABSTRACT: Synthesis of extracellular adenosine by the ectonucleotidases CD39 and CD73 represents an important pathway of immune suppression in the tumor microenvironment. Using two mouse models ( RET transgenic melanoma and Panc02 orthotopic pancreatic adenocarcinoma), we identified an elevated frequency of ectonucleotidase-expressing T cells in tumors and spleens. Importantly, these ectonucleotidase-positive T cells also showed a pronounced expression of PD-1. Conversely, the PD-1 + T cell subsets in tumors contained substantially larger proportions of ectonucleotidase-expressing cells compared to their counterparts lacking PD-1 expression. Our in vitro experiments showed that the activation of normal T cells resulted in an increase in the CD39 expression. CD39 + and CD73 + T cells displayed effector or memory phenotypes and produced IFN-γ, thereby linking ectonucleotidase expression to T cell effector functions. An accumulation of conventional and regulatory T cells expressing CD39 and/or CD73 was also detected in the peripheral blood of patients with melanoma and pancreatic cancer. Moreover, we demonstrated a significant association between low frequencies of circulating CD73 + CD8 + T cells and CD73 + CD4 + regulatory T cells and better overall survival of melanoma patients. Tumor-derived soluble factors (in particular, TGF-β) significantly enhanced the frequencies of ectonucleotidase-expressing cells in mice. Our findings suggest that the upregulation of ectonucleotidase expression in T cells promotes extracellular adenosine accumulation and represents an important mechanism of homeostatic immune auto-regulation, which could be hijacked by tumors to evade anti-cancer immunity. Targeting CD39 and CD73 can open new avenues for cancer immunotherapy. … (more)
- Is Part Of:
- Oncoimmunology. Volume 9:Number 1(2020)
- Journal:
- Oncoimmunology
- Issue:
- Volume 9:Number 1(2020)
- Issue Display:
- Volume 9, Issue 1 (2020)
- Year:
- 2020
- Volume:
- 9
- Issue:
- 1
- Issue Sort Value:
- 2020-0009-0001-0000
- Page Start:
- Page End:
- Publication Date:
- 2020-01-01
- Subjects:
- Melanoma -- pancreatic adenocarcinoma -- ectonucleotidases -- adenosine -- effector T cells -- immunosuppression
Tumors -- Immunological aspects -- Periodicals
Neoplasms -- therapy -- Periodicals
Immunotherapy -- Periodicals
616.994 - Journal URLs:
- http://www.landesbioscience.com/journals/oncoimmunology/ ↗
http://www.tandfonline.com/toc/koni20/current ↗
http://www.tandf.co.uk/journals/ ↗ - DOI:
- 10.1080/2162402X.2020.1744946 ↗
- Languages:
- English
- ISSNs:
- 2162-402X
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 26299.xml